The intracellular signalosome of PD-L1 in cancer cells

por Escors, David, Gato-Cañas, María, Zuazo, Miren, Arasanz, Hugo, García-Granda, María Jesus, Vera, Ruth, Kochan, Grazyna
Publicado 2018

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

por Chocarro de Erauso, Luisa, Zuazo, Miren, Arasanz, Hugo, Bocanegra, Ana, Hernandez, Carlos, Fernandez, Gonzalo, Garcia-Granda, Maria Jesus, Blanco, Ester, Vera, Ruth, Kochan, Grazyna, Escors, David
Publicado 2020

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

por Zuazo, Miren, Arasanz, Hugo, Fernández‐Hinojal, Gonzalo, García‐Granda, Maria Jesus, Gato, María, Bocanegra, Ana, Martínez, Maite, Hernández, Berta, Teijeira, Lucía, Morilla, Idoia, Lecumberri, Maria Jose, Fernández de Lascoiti, Angela, Vera, Ruth, Kochan, Grazyna, Escors, David
Publicado 2019

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

por Bocanegra, Ana, Fernandez-Hinojal, Gonzalo, Zuazo-Ibarra, Miren, Arasanz, Hugo, Garcia-Granda, Maria Jesus, Hernandez, Carlos, Ibañez, Maria, Hernandez-Marin, Berta, Martinez-Aguillo, Maite, Lecumberri, Maria Jose, Fernandez de Lascoiti, Angela, Teijeira, Lucia, Morilla, Idoia, Vera, Ruth, Escors, David, Kochan, Grazyna
Publicado 2019

The multi-specific V(H)-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

por Edwards, Carolyn J., Sette, Angelica, Cox, Carl, Di Fiore, Barbara, Wyre, Chris, Sydoruk, Daniela, Yadin, David, Hayes, Philip, Stelter, Szymon, Bartlett, Phillip D., Zuazo, Miren, Garcia-Granda, Maria Jesus, Benedetti, Giovanni, Fiaska, Stratoniki, Birkett, Neil R., Teng, Yumin, Enever, Carrie, Arasanz, Hugo, Bocanegra, Ana, Chocarro, Luisa, Fernandez, Gonzalo, Vera, Ruth, Archer, Bethan, Osuch, Isabelle, Lewandowska, Martyna, Surani, Yasmin M., Kochan, Grazyna, Escors, David, Legg, James, Pierce, Andrew J.
Publicado 2021